Enhancing the Therapeutic Efficacy of KRAS(G12C) Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90

BACKGROUND: KRAS(G12C) inhibitors have shown promising efficacy in early clinical trials, but drug resistance compromises their long-term benefits. Therefore, it is critical to understand the mechanisms of drug resistance and to design appropriate combinatory treatments to improve efficacy. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Wu, Lei, Lu, Hong, Wu, En, Ni, Jun, Zhou, Xiaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632397/
https://www.ncbi.nlm.nih.gov/pubmed/34858498
http://dx.doi.org/10.1155/2021/2721466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632397/
https://www.ncbi.nlm.nih.gov/pubmed/34858498
http://dx.doi.org/10.1155/2021/2721466

Ejemplares similares